Description

HT-144 is a malignant human melanoma cell line that displays aneuploid fibroblastic morphology and grows in adherent tissue culture. This cell line has been reported to be nonpermissive for human cytomegalovirus (HCMV). HT-144 cells form xenograft tumors when injected into immunocompromised mice. These cells contain a mutation in the ATM gene, resulting in the expression of a truncated protein, which causes increased sensitivity to UVB and ionizing radiation compared to other melanoma cell lines. The HT-144 cells also express mutant B-Raf (V600E).

Source

This cell line was established in 1966 from a metastatic site (subcutaneous tissue) in a 29-year-old Caucasian male with malignant melanoma.

Inventors

• Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
• Germaine Trempe, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

• Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59: 221-226 (PubMed ID: 327080)
• Smith JD (1986) Human cytomegalovirus: demonstration of permissive epithelial cells and nonpermissive fibroblastic cells in a survey of human cell lines. Journal of Virology 60: 583-588 (PubMed ID: 3021992)
• Ramsay J et al. (1998) Radiosensitive melanoma cell line with mutation of the gene for ataxia telangiectasia. British Journal of Cancer 77: 11-14 (PubMed ID: 9459139)
• Chen B et al. (2012) BRAFV600E negatively regulates the AKT pathway in melanoma cell lines. PLoS One 7: e42598 (PubMed ID: 22880048)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

• Express License:  For internal research purposes by a for-profit entity:  1) Fill out MSK’s ATCC Express License, see here for links to the online fillable ATCC Express License, as well as a PDF version.  2) After execution by MSK, you will receive a signed copy, and can then place your order with ATCC. For detailed guidance on how to fill out this webform, see here. Please note:  In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. This license is only available for select cell lines, including this one. Once this license has been executed by MSK, you will receive a signed copy and payment instructions; all payments up to $10,000 must be made by credit card.
• Commercial License: Contact MSK’s Tangible Materials team at TRMOTDRTM@mskcc.org.
• For non-licensing requests from academic-research institutions: Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, weisgarf@mskcc.org